Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Authors:

Abstract
In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain and relapse. We conducted a cost-utility analysis of lurasidone versus aripiprazole from the perspective of healthcare services, using Scotland and Wales as specific case studies.

This publication has 39 references indexed in Scilit: